Articles On Dimerix (ASX:DXB)

Dimerix (ASX: DXB) has received final data analysis from the international PARASOL collaboration that reinforces support for proteinuria-based endpoints in its pivotal Phase 3 Action3 study on DMX-200 for the treatment of kidney disease. Th...

PainChek can now tackle the US$100 million US aged-care market – while other geographies beckon Trivarx shares leap 9% on depression detection trial results Dimerix gets more assurances on using surrogate endpoints in its pivotal kidney t...

ASX closes 0.16% lower with nine of the 11 sectors in the red; materials led gainers; energy was leader of the laggards RBA keeps rates on hold at 3.6%, citing concerns inflation in the September quarter may be higher than expected Embedde...

Dimerix secures orphan drug designation for DMX-200 in Focal Segmental Glomerulosclerosis in Japan ACTION3 phase III clinical trial currently recruiting in Japan to support potential marketing approval in country FUSO Pharmaceutical Indust...

After a strategy revamp, Noxopharm is targeting inflammatory diseases – lupus in particular Affecting five million people, lupus has proved a tricky disease to tackle The company is pondering a phase II trial, most likely in skin lupus No...

Pitt Street Research says Imagion is significantly undervalued and sits around 75-80% below target range of 12.3 to 14.9 cents per share Research house sees further upside if MagSense imaging agent tech progresses to commercialisation in a...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Dimerix boss Dr Nina Webster to join Imagion Biosystems as non-executive director Webster has extensive experience with ASX healthcare companies and is also non-executive chair of SYNthesis BioVentures Appointment comes as Imagion prepares...

Ignite Partners is bringing the buzz to Hong Kong with a two-day power event packed with dynamic one-on-ones between top CEOs and hand-picked investors. The Grand Ballroom, 1 Harbour Road, Wan Chai, Hong Kong 15 – 16 October 2025 Pre-ar...

Morgans’ Scott Power describes mood at Bioshares Biotech Summit as “markedly more upbeat than prior years” with signs of a rotation back to ASX healthcare sector Power highlights nine ASX healthcare companies from summit with clear near-te...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Highlights: ASX 200 trims early losses as sectors rebound Viva Energy under pressure after first-half update Lithium and uranium stocks show mixed reactions The ASX 200 began Tuesday’s session in the red, touching earl...

Prescient at critical stage of development with phase 2a trial underway for PTX-100 PTX-100 granted orphan drug and fast track designations by the US FDA, unlocking benefits Focus on advancing PTX-100 to potential registrational phase 2b t...

The S&P/ASX 200 Index (ASX: XJO) is having a positive start to the week. At the time of writing, the benchmark index is up 0.25% to 8,689.1 points. Four ASX shares that are rising more than most today are listed below. Here's why they a...

Highlights: Dimerix gains on milestone-rich licensing agreement Newmont lifts after delivering strong quarterly performance Titomic jumps following a successful capital raise As the broader S&P/ASX 200 index trades...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and on track to record a disappointing decline. At the time of writing, the benchmark index is down 0.5% to 8,664.4 points. Four ASX shares that are not letting that ho...

S&P/ASX 200 Index (ASX: XJO) gold stock Newmont Corp (ASX: NEM) is charging higher today. Newmont shares closed yesterday trading for $91.88. In morning trade on Friday, shares are changing hands for $96.01 apiece, up 4.5%. This sees Ne...

On Friday the 13th of December last year, Percheron Therapeutics (ASX:PER)  CEO Dr James Garner awaited the top-line results of the phase IIb Duchenne muscular dystrophy trial from his Brisbane lounge room. The company’s clinical developmen...

 Nanosonics has launched tweaked versions of its Trophon medical probe steriliser Amplia shares soar a further 36% on pancreatic cancer promise Dimerix looks to broaden its repertoire     Nanosonics (ASX:NAN) has launched updated iteratio...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

With the FDA’s blessing, Dimerix will use phase III trial endpoints that could lead to accelerated approval for its kidney disease drug Dimerix is confident of phase III success because an expert ‘peek’ at the blinded data shows it’s on th...

Tetratherix’s listed life starts on a solid note Dimerix pockets a $4.2 million milestone – with close to $1.4 billion to come Orthocell chalks up first commercial US procedure for its Remplir device Today’s ASX debut of wound management...

Botanix Pharmaceuticals (ASX:BOT) CEO Dr Howie McKibbon says investors shouldn’t rely just on management’s assertion that its anti-sweating drug Sofdra has – and we paraphrase – “the potential to be the world’s most successful dermatology d...

ASX pulls back from 0.55pc slide to dip 0.21pc Utilities leads recovery, up 0.74pc ASX All Ord Gold index climbs 0.62pc   ASX pulls out of tailspin to make up ground While the ASX closed lower today, down 0.21%, it was looking a lot worse...

Dimerix reports 200 adult patients now randomised and dosed in ACTION3 phase III trial in FSGS patients Number represents ~70% of adult patients to be dosed in the pivotal two-year trial Patients recruitment remains on track to complete do...

Highlights: ASX health sector eased, diverging from the broader ASX 200 gains during the week EMVision expanded its pivotal trial and welcomed Ramsay Health Care CEO to the board Dimerix launched clinical activities in Japan...

ASX health stocks dipped 0.82% over the past five days while the broader market has risen 1.26% EMVision appoints Ramsay Health Care CEO to board and expands sites of pivotal trial First Japan site opens for Dimerix’s phase III clinical tr...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

First site in Japan opens for Dimerix’s ACTION3 phase III clinical trial of DMX-200 in rare kidney disease Opening of trial site triggers first development milestone payment of ¥400 million (~A$4.3m) to Dimerix Further sites forecast to op...

The ASX 200 is looking to end Week 22 on a downward tilt, with endless Trump tariff changes likely to push the Aussie bourse towards a mildly red close. Listen to the HotCopper podcast for in-depth discussions and insights on all the big...

Dimerix (ASX:DXB) has kicked off a key trial in Japan (in terms of patient recruitment) seeking to treat inflammatory diseases. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throu...

AI is reshaping microbiology in the labs Big Pharma taps Clever Culture’s APAS system Here are ASX biotechs with global health deals    Step into a modern microbiology lab today and you might notice something’s different. The culture plat...

ASX slides 0.45pc, falling from new 50-day high Gold and resources stocks temper losses Info Tech sector leads market down   After a month of almost uninterrupted gains, the ASX has taken a dip today, shedding 0.45%. The combination of Mo...

AFT Pharmaceuticals boosts revenue, but profits still lag Telix Pharmaceuticals chair and CEO reflect on a prosperous 2024 – and promise more riches to come Dimerix’s pivotal trail passes another safety check   The bourse’s ‘forgotten’ dr...

Australia has become well-known for its paediatric drug discovery with several life-altering treatments CSL is a global leader in developing therapies for children with haemophilia and other serious blood disorders Neurotech International...

As a former bus driver, Dimerix (ASX:DXB) CEO Dr Nina Webster knows that the drug development journey is just as important as the destination when it comes to delivering value to shareholders. The therapeutic trip can be painfully long, esp...

With the gold price hovering near all-time highs, should you buy S&P/ASX 200 Index (ASX: XJO) gold stocks or gold exchange-traded funds (ETFs)? We'll dig into that million-dollar question below. But first… What's been sending the gold...

Highlights Dimerix (DMX) leads the gains on renewed attention around pharmaceutical developments Tempest Minerals (TEM) climbs following resource news related to the Remorse iron deposit Dreadnought Resources (DRE) declines...

Boss Energy Ltd (ASX: BOE) shares have enjoyed a tremendous run over the past month. How tremendous? Well, on 7 April, the S&P/ASX 200 Index (ASX: XJO) uranium stock closed the day trading for $2.10. At market close yesterday, those sa...

Highlights: Dimerix Limited has quoted additional ordinary securities on the ASX. The development follows conversion of previous instruments into tradeable shares. ASX:DXB remains focused on advancing kidney disease treatmen...

The NextDC Ltd (ASX: NXT) share price has surged over the last couple of weeks, gaining about 30%. The data centre operator's share price added to its run on Tuesday, rising around 8% with some positive news coming out of the company....

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brokers have named as buys this week are lis...

If you are on the hunt for some new ASX 200 stocks to buy, then it could be worth listening to what Goldman Sachs is saying about the two listed below. They have both been named on its highly coveted Asia-Pacific conviction list in May, whi...

The S&P/ASX 200 Index (ASX: XJO) endured another negative trading day this Tuesday, building on the losses we saw kick off the trading week yesterday. By the time the markets shut, the ASX 200 had...

The S&P/ASX 200 Index (ASX: XJO) is having a subdued session on Tuesday. In afternoon trade, the benchmark index is down slightly to 8,156.1 points. Four ASX shares that are falling more than most today are listed below. Here's why the...

Dimerix receives upfront payment of US$30 million for US licensing deal of DMX-200 Company eligible for further potential development milestones of up to US$560 million plus tiered royalties Fourth license deal executed for phase III clini...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is no course to record a small decline. At the time of writing, the benchmark index is down almost 0.2% to 8,144.3 points. Four ASX shares that are not letting that hold them back are...

By now, you've probably read a million articles about Warren Buffett stepping down. Yes, the great man has hit the headlines again. No, this won't be one of those articles. This one is about chocolate, and it ends with two ASX stocks you mi...

The NextDC Ltd (ASX: NXT) share price is charging higher today. Shares in the S&P/ASX 200 Index (ASX: XJO) data centre operator and developer closed yesterday trading for $12.66. In morning trade on Tuesday, shares are changing hands fo...

The US health sector shows signs of stabilising as chaos subsides Immutep will meet with the FDA following “excellent” follow-on trial results When it comes to its sagging share price, Immuron leaves blame-shifting to the defeated Liberals...